Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer

A. Vigani, F. Pensa, F. Vaira, L. Bancalari, S. Cordani, R. Maggiani, P. Canessa, P. Pronzato

Research output: Contribution to journalArticle

Abstract

16 patients with advanced small cell lung cancer were treated with a combination of cyclophosphamide (1000 mg/m 2 day 1), epidoxorubicin (60 mg/m 2 day 1) and vincristine (1.4 mg/m 2 day 1) every 14 days for six cycles followed by a combination of cisplatin (40 mg/m 2 clays 1 and 2) and etoposide (100 mg/m 2 days 1-3) every 14 days for four cycles. Shortening of intervals was obtained with the prophylactic employment of granulocyte colony-stimulating factor (filgrastim, 300 mcg subcutaneously from day 5 to dsy 10). In 11 patients ratio between actually delivered dose intensity and planned dose intensity of >80% was obtained. Toxicity was acceptable and no life-threatening toxicities were observed. An objective response (partial or complete) was observed in 11 patients. The new regimen, incorporating the concepts of dose-intensification and sequential administration of regimens, is feasible and may be considered for further studies.

Original languageEnglish
Pages (from-to)4015-4018
Number of pages4
JournalAnticancer Research
Volume20
Issue number5 C
Publication statusPublished - 2000

Keywords

  • Chemotherapy dose intensity
  • Filgrastim
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Vigani, A., Pensa, F., Vaira, F., Bancalari, L., Cordani, S., Maggiani, R., Canessa, P., & Pronzato, P. (2000). Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer. Anticancer Research, 20(5 C), 4015-4018.